Flucytosine. An effective oral treatment for chromomycosis

Mauceri, A. A.

doi:10.1001/archderm.109.6.873

Cited by 14 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Frequent development of resistance to 5-FC during therapy has restricted its use as a single drug in the treatment of fungal infections (4,14). However, 5-FC can be used effectively in combination with amphotericin B.…”

mentioning

confidence: 99%

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora

Harris¹,

Manning²,

Federle³

et al. 1986

Antimicrob Agents Chemother

117

View full text Add to dashboard Cite

The mechanism of toxicity from 5-fluorocytosine chemotherapy is unclear. However, recent evidence suggests that the generation of 5-fluorouracil by a host may play an important role in the development of this toxicity. Using an in vitro semicontinuous culture system to mimic the intestinal microflora, we examined the capacity of this complex microbial community to convert 5-fluorocytosine to 5-fluorouracil. The system was dosed initially and after 2 weeks of chronic exposure to 5-fluorocytosine with radiolabeled 5-fluorocytosine. No detectable production of 5-fluorouracil was observed up to 8 h after the acute dose; however, at 24 h and at all time points thereafter, increasing levels of 5-fluorouracil were detected for 4 days. The chronic dose resulted in an increased rate of 5-fluorouracil production without the 8-h lag time. These findings suggest that the enzyme or enzymes responsible for the deamination of 5-fluorocytosine to 5-fluorouracil by the intestinal microflora can be induced by chronic exposure to 5-fluorocytosine and that this conversion may provide a mechanism through which 5-fluorocytosine toxicity is manifested.

show abstract

mentioning

confidence: 99%

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora

Harris¹,

Manning²,

Federle³

et al. 1986

Antimicrob Agents Chemother

117

View full text Add to dashboard Cite

show abstract

“…The drug regimen has not been well studied. Several case reports showed that systemic flucytosine (150 mg/kg/day), 9 itraconazole (200 mg/day), 10 ketoconazole (200 mg/day), 11 and intravenous amphotericin B have been helpful, but relapse is not uncommon. Intralesional amphotericin B (30–50 mg/day) was reported to be helpful 8 .…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous Phaeohyphomycotic Cysts Caused by Exophiala jeanselmei in a Lung Transplant Patient

Xu¹,

Low²,

Palevsky³

et al. 2001

Dermatol Surg

View full text Add to dashboard Cite

show abstract

“…5-Flucytosine (5-FC) is an antimetabolite drug with excellent activity against Candida spp, Cryptococcus neoformans and Chromomycosis spp (22, 23). Resistance develops rapidly to 5-FC mono-therapy, so clinicians have reserved it for combination therapy to augment other antifungals.…”

Section: Nucleoside Analogsmentioning

confidence: 99%

Pharmacokinetics of antifungal agents in children

Watt

Benjamin

Cohen‐Wolkowiez

2011

Early Human Development

View full text Add to dashboard Cite

Invasive fungal infections in immunocompromised children are common and often fatal. The first antifungal agents such as amphotericin B and fluconazole offered effective treatment, but their use was often limited by toxicity and resistance. Numerous new antifungal agents have since been developed and appear to be as effective. Most dosing and safety trials have been done in adults, and extrapolation of this data to children has proven inadequate. We reviewed the literature regarding the pharmacokinetics/pharmacodynamics (PK/PD) and safety of antifungal agents with an emphasis on the newer azoles and echinocandins. From a small but growing number of PK/PD trials, better dosing guidelines have been developed.

show abstract

Flucytosine. An effective oral treatment for chromomycosis

Cited by 14 publications

References 0 publications

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora

Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora

Subcutaneous Phaeohyphomycotic Cysts Caused by Exophiala jeanselmei in a Lung Transplant Patient

Pharmacokinetics of antifungal agents in children

Contact Info

Product

Resources

About